![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Zogenix’s Fintepla Approved for Rare Form of Epilepsy
Zogenix’s Fintepla Approved for Rare Form of Epilepsy
June 29, 2020
The FDA has approved Zogenix’s Fintepla (fenfluramine) for seizures associated with Dravet syndrome, a rare form of epilepsy, in patients age 2 years and older.
The approval was based on the results of two clinical trials, in which patients treated with Fintepla had significantly greater reductions in seizures than those who received a placebo.
The FDA is requiring a boxed warning for the drug on the risk of heart disease and hypertension.
Upcoming Events
-
21Oct